SCHEMBL7689130

SCHEMBL7689130

CCOC(=O)c1c(-c2ccncc2)[nH]c(-c2ccncc2)c1-c1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.57
HPGD P15428 4/20 0.57
LMNA P02545 3/20 0.57
MAPT P10636 3/20 0.57
KDM4E B2RXH2 2/20 0.57
GAA P10253 2/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
NPSR1 Q6W5P4 2/20 0.57
NPC1 O15118 1/20 0.57
RAB9A P51151 1/20 0.57
MDM2 Q00987 4/20 0.52
TP53 P04637 1/20 0.52
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
HSD17B10 Q99714 2/20 0.51
MAPK10 P53779 1/20 0.51
CHEK1 O14757 2/20 0.51
EGFR P00533 2/20 0.51
KDR P35968 2/20 0.51
CDC7 O00311 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2662802 0.93 MAPK14 (0.55) ALDH1A1HPGDLMNAMAPTKDM4E
SCHEMBL4184780 0.88 CSNK1A1 (0.62) ALDH1A1HPGDLMNAMAPTKDM4E
SCHEMBL7696380 0.88 CSNK1A1 (0.62) ALDH1A1HPGDLMNAMAPTKDM4E
SCHEMBL31567904 0.83 ALDH1A1 (0.62) ALDH1A1HPGDLMNAMAPTKDM4E
SCHEMBL31567905 0.83 ALDH1A1 (0.62) ALDH1A1HPGDLMNAMAPTKDM4E
SCHEMBL7686682 0.83 AR (0.64) MAPTGAASMN1; SMN2RAB9AMDM2
SCHEMBL7686215 0.82 ALDH1A1 (0.51) ALDH1A1HPGDLMNAKMT2AHSD17B10
SCHEMBL7688692 0.82 CSNK1A1 (0.69) ALDH1A1HPGDLMNAMAPTKDM4E
SCHEMBL7687321 0.80 CSNK1A1 (0.62) ALDH1A1MAPTSMN1; SMN2MDM2CHEK1
SCHEMBL2646215 0.80 GCGR (0.52) GCGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6417202-B1 3-ACETYL-4-METHYL-2,5-DI(4-PYRIDYL)-1H-PYRROLE, FOR EXAMPLE; TREATING CELL ADHESION MOLECULES (CAMS) MEDIATED DISEASES SUCH AS ARTHRITIS, AIDS, SEPTIC SHOCK, CACHEXIA, TRANSPLANT REJECTION PFIZER INC. 2002-07-09 US disclosed
US-20020049235-A1 3-acetyl-4-methyl-2,5-di(4-pyridyl)-1H-pyrrole, for example; treating cell adhesion molecules (CAMs) mediated diseases such as arthritis, AIDS, septic shock, cachexia, transplant rejection PFIZER PHARMACEUTICALS INC. (JP) 2002-04-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020049235-A1 3-acetyl-4-methyl-2,5-di(4-pyridyl)-1H-pyrrole, for example; treating cell adhesion molecules (CAMs) mediated diseases such as arthritis, AIDS, septic shock, cachexia, transplant rejection ICAM1, VCAM1, CD14 ALDH1A1 443/4885HPGD 1474/4885LMNA 4824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.